New cancer treatment trial targets multiple advanced tumors
NCT ID NCT05307874
Summary
This study tested a new immunotherapy combination (ICT01 plus low-dose IL-2) for people with advanced solid tumors that had stopped responding to standard treatments. The trial aimed to determine if this combination was safe and could help control cancer growth. It involved 56 participants with specific advanced cancers including colorectal, ovarian, prostate, pancreatic, and melanoma.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR, ADULT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
IUCT Oncopole Claudius Regaud
Toulouse, France
-
Institute Gustave Roussy
Paris, France
-
The Institute of Cancer Research
Sutton, United Kingdom
-
University Carl Gustav Carus
Dresden, Germany
-
Universitätsklinikum Wuerzburg
Würzburg, Germany
Conditions
Explore the condition pages connected to this study.